Latest Dublin Prices

Aer Lingus 2.37 -0.05 more
BoI 0.26 -0.02 more
CRH 21.70 -0.03 more
Glanbia 14.35 -0.30 more
Greencore 0.64 -0.02 more
Ind. News 0.12 0.01 more
Ryanair 10.44 -0.12 more


Roche's cancer drug profit target

Thursday, July 24 08:42:20

Swiss drugmaker Roche confirmed its full-year sales and profit targets on Thursday as growing momentum for its new breast cancer medicines and professional diagnostics products countered the effects of a strong Swiss franc.

Unlike other pharmaceutical companies that have been ravaged by patent losses, Roche has yet to face a challenge to its older biotech drugs by makers of copycat treatments and has launched a string of new, expensive cancer medicines.

The Basel-based firm hopes these so-called follow-on drugs will help it defend sales in its breast and blood cancer businesses once generic competition arrives.

Its strategy looked sound after first-half sales of Perjeta, which targets the same protein found on some cancer cells as Roche's older blockbuster Herceptin, surged 276 percent to 388 million Swiss francs ($429.68 million).

Another breast cancer drug Kadcyla notched up 227 million in sales, compared to 83 million a year earlier.

Roche also won approval for Gazyva, a follow-on to its top-seller MabThera in the United States last November. The drug chalked up sales of 18 million in the first half.

A strong performance in its professional diagnostics business, where sales rose 9 percent, also helped to offset flat sales in its diabetes care unit.


For more visit